Noxopharm
(ASX:NOX) is seeing some movement to their board with Group CEO and Executive Director Graham Kelly moving to Executive Chairman.
Peter Marks is moving from Non-Executive Chairman to Non Executive Deputy Chairman.
The changes have been prompted by a strategic decision to start the process of raising the Company’s profile in the US including a listing of its securities on the Nasdaq.
Medical Director Beata Niechoda will join as a Special Advisor to the Board.
Graham and Beata will complement the function of Greg van Wyk as Noxopharm CEO and CMO, and guide Veyonda? through clinical phases.
Greg will be assisted by the appointment of Jeanette Bell as Chief Operating Officer.
Shares in Noxopharm
(ASX:NOX) closed flat at 48 cents on Thursday.
